Skip to main content
. 2018 Feb 26;131(21):2357–2366. doi: 10.1182/blood-2017-12-820910

Figure 3.

Figure 3.

PFS and OS. Kaplan-Meier estimates of PFS and OS of all patients on study (A-B), and by cohort and treatment status (C-D and E-F, respectively); (C-D) for the TP53 cohort and (E-F) for the elderly cohort B. RR, relapsed and/or refractory CLL; TN, treatment-naïve CLL.